Related Experiment Video

Updated: Nov 27, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.5K

Microbiota-based Therapies Clostridioides difficile infection that is refractory to antibiotic therapy

Shama R Mehta1, Eugene F Yen1

  • 1NorthShore University HealthSystem, Division of Gastroenterology, 2650 Ridge Avenue, Suite G221, Evanston, IL 60201.

Translational Research : the Journal of Laboratory and Clinical Medicine
|December 5, 2020
PubMed

Insights

Clostridioides difficile infection (CDI) is a serious global health threat, particularly for older adults. Fecal Microbiota Transplantation (FMT) offers a safe and effective solution for recurrent CDI (rCDI) when patients undergo proper screening.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Gastroenterology

Background:

  • Clostridioides difficile infection (CDI) causes significant global mortality, especially in the elderly.
  • Recurrent CDI (rCDI) is increasing and challenging to treat with antibiotics alone.
  • Fecal Microbiota Transplantation (FMT) is a promising therapeutic option for rCDI.

Purpose of the Study:

  • To review current treatments for CDI.
  • To focus on microbiota-based therapies for antibiotic-refractory CDI.
  • To discuss the safety and efficacy of FMT for rCDI.

Main Methods:

  • Literature review of current CDI treatments.
  • Focus on studies investigating FMT for rCDI.
  • Analysis of safety reports and screening protocols for FMT.

Main Results:

  • FMT is a consistently effective treatment for rCDI.
  • Recent safety concerns regarding pathogen transmission have been reported.
  • Appropriate screening ensures safe administration of FMT.
  • FMT significantly impacts rCDI eradication and patient quality of life.

Conclusions:

  • FMT is a vital therapeutic strategy for managing rCDI.
  • Careful patient screening is essential for safe FMT implementation.
  • Microbiota-based therapies represent a key advancement in treating refractory CDI.

More Related Videos

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.2K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R2029106:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.9K

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
308
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
315
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
524
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
690
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
455
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
335